Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Non-Current Assets came in at $564.4 million in Q2 2026, up 35.4% on a YoY basis from $416.9 million in Q2 2025, and up 368797.39% quarter-over-quarter from $153000.0 in Q1 2026.
Analysis
Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Non-Current Assets for 6 consecutive years, with $564.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets rose 35.4% year-over-year to $564.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (up 5.82% YoY), and the FY2026 full-year result was $153000.0, down 24.26% from the prior year.
- Non-Current Assets rose to $564.4 million in Q2 2026 per ROIV's latest filing, from $153000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $4.3 billion in Q4 2025 and bottomed at $153000.0 in Q1 2026.
- Historically, Non-Current Assets has averaged $822.1 million across 5 years, with a median of $532.4 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets jumped 257.11% in 2023, then slumped 98.6% in 2025.
- Over 5 years, Non-Current Assets stood at $556.7 million in 2022, then surged by 257.11% to $2.0 billion in 2023, then gained by 17.73% to $2.3 billion in 2024, then jumped by 83.05% to $4.3 billion in 2025, then plunged by 86.83% to $564.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $564.4 million, $153000.0, and $4.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Insmed | 27.84 Bn | 26.68 Bn | 358.27 Mn | 468.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 564.41 Mn |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 4.28 Bn |
| Sep 30, 2025 | 550.95 Mn |
| Jun 30, 2025 | 416.85 Mn |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 2.34 Bn |
| Sep 30, 2024 | 404.91 Mn |
| Jun 30, 2024 | 494.95 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 1.99 Bn |
| Sep 30, 2023 | 513.92 Mn |
| Jun 30, 2023 | 575.49 Mn |
| Mar 31, 2023 | 591.02 Mn |
| Dec 31, 2022 | 556.73 Mn |
| Sep 30, 2022 | 500.67 Mn |
| Jun 30, 2022 | 560.96 Mn |
| Mar 31, 2022 | 438.61 Mn |
| Dec 31, 2021 | 511.84 Mn |
| Sep 30, 2021 | 547.15 Mn |